Adriamycin CS

Adriamycin CS Adverse Reactions

doxorubicin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Full Prescribing Info
Adverse Reactions
Adverse reactions reported in association with doxorubicin therapy are listed as follows by MedDRA System Organ Class and by frequency. Frequencies are defined as: Very common (≥10%), Common (≥1%, <10%), Uncommon (≥0.1%, <1%), Rare (≥0.01%, <0.1%), Very rare (<0.01%) and Not known (cannot be estimated from available data). (See Table 3.)

Click on icon to see table/diagram/image

Intravesical Use: Systemic toxicity is not a common problem, however, adverse reactions have been noted at doses exceeding that recommended (see DOSAGE & ADMINISTRATION).
Local reactions observed include chemical cystitis, contraction of the bladder, haematuria, painful micturition, frequency and urgency. These disturbances are transient.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in